ARID1A and cancer: Notably, the short-term advantage provided by the immune exclusion phenotype associated with mutant ARID1A clones could also confer a pro-oncogenic function long-term (Li et al, 2020), explaining the role of ARID1A as a driver gene in colitis-associated cancer.